Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 11, 2015, Pages 3421-3426

  Turner, Kristen M ^a,d   Sun, Youting ^a,e   Ji, Ping ^a   Granberg, Kirsi J ^a,b   Bernard, Brady ^c   Hu, Limei ^a   Cogdell, David E ^a   Zhou, Xinhui ^a   Yli Harja, Olli ^b   Nykter, Matti ^b   Shmulevich, Ilya ^c   Yung, W K Alfred ^a   Fuller, Gregory N ^a   Zhang, Wei ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SEQUENOM INC   (United States)

Author keywords

Akt; DNA repair; Glioma; RCAS tv a mouse model

Indexed keywords

AKT3 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ESTROGEN RECEPTOR ALPHA; PROTEIN KINASE B; UNCLASSIFIED DRUG; DACARBAZINE; ISOENZYME; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA DAMAGE; DNA END JOINING REPAIR; DNA REPAIR; GENE AMPLIFICATION; GLIOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN TUMOR; CHEMISTRY; DISEASE COURSE; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN GENOME; METABOLISM; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; RADIATION RESPONSE; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DACARBAZINE; DISEASE PROGRESSION; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; GLIOMA; HUMANS; ISOENZYMES; MICE; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84925242229     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1414573112     Document Type: Article

References (42)

1. Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24(50):7455-7464.
2. Gonzalez E, McGraw TE (2009) The Akt kinases: Isoform specificity in metabolism and cancer. Cell Cycle 8(16):2502-2508.
3. Khan KH, Yap TA, Yan L, Cunningham D (2013) Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J Cancer 32(5):253-265.
4. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216): 1061-1068.
5. Brennan CW, et al.; TCGA Research Network (2013) The somatic genomic landscape of glioblastoma. Cell 155(2):462-477.
6. Wang H, et al. (2004) Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest 84(8):941-951.
7. Cheng GZ, et al. (2008) Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr Cancer Drug Targets 8(1):2-6.
8. Dillon RL, Muller WJ (2010) Distinct biological roles for the akt family in mammary tumor progression. Cancer Res 70(11):4260-4264.
9. Maroulakou IG, Oemler W, Naber SP, Tsichlis PN (2007) Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res 67(1):167-177.
10. Chin YR, Toker A (2010) The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration. Mol Cell 38(3):333-344.
11. Iliopoulos D, et al. (2009) MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal 2(92):ra62.
12. Villagrasa P, et al. (2012) Akt2 interacts with Snail1 in the E-cadherin promoter. Oncogene 31(36):4022-4033.
13. Pu P, Kang C, Li J, Jiang H (2004) Antisense and dominant-negative AKT2 cDNA inhibits glioma cell invasion. Tumour Biol 25(4):172-178.
14. Pu P, Kang C, Li J, Jiang H, Cheng J (2006) The effects of antisense AKT2 RNA on the inhibition of malignant glioma cell growth in vitro and in vivo. J Neurooncol 76(1): 1-11.
15. Michiue H, Eguchi A, Scadeng M, Dowdy SF (2009) Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma. Cancer Biol Ther 8(23):2306-2313.
16. Mure H, et al. (2010) Akt2 and Akt3 play a pivotal role in malignant gliomas. Neurooncol 12(3):221-232.
17. Endersby R, Zhu X, Hay N, Ellison DW, Baker SJ (2011) Nonredundant functions for Akt isoforms in astrocyte growth and gliomagenesis in an orthotopic transplantation model. Cancer Res 71(12):4106-4116.
18. Cheung M, Sharma A, Madhunapantula SV, Robertson GP (2008) Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 68(9): 3429-3439.
19. Shao Y, Aplin AE (2010) Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res 70(16):6670-6681.
20. O'Hurley G, et al. (2014) Investigation of molecular alterations of AKT-3 in triple-negative breast cancer. Histopathology 64(5):660-670.
21. Nakatani K, et al. (1999) Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 274(31): 21528-21532.
22. Banerji S, et al. (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486(7403):405-409.
23. Easton RM, et al. (2005) Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol 25(5):1869-1878.
24. Holmes KM, et al. (2012) Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network. Proc Natl Acad Sci USA 109(9):3475-3480.
25. Dunlap SM, et al. (2007) Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA 104(28):11736-11741.
26. Moore LM, et al. (2009) IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. Proc Natl Acad Sci USA 106(39): 16675-16679.
27. Sanidas I, et al. (2014) Phosphoproteomics screen reveals akt isoform-specific signals linking RNA processing to lung cancer. Mol Cell 53(4):577-590.
28. Horman SR, et al. (2013) Akt-mediated phosphorylation of argonaute 2 down-regulates cleavage and upregulates translational repression of MicroRNA targets. Mol Cell 50(3):356-367.
29. Jin Q, et al. (2014) Transcriptional and posttranslational regulation of insulin-like growth factor binding protein-3 by Akt3. Carcinogenesis 35(10):2232-2243.
30. Grabinski N, et al. (2014) AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice. Cell Signal 26(5):1021-1029.
31. Corum DG, Tsichlis PN, Muise-Helmericks RC (2014) AKT3 controls mitochondrial biogenesis and autophagy via regulation of the major nuclear export protein CRM-1. FASEB J 28(1):395-407.
32. Grantham R (1974) Amino acid difference formula to help explain protein evolution. Science 185(4154):862-864.
33. Ernst DS, et al. (2005) Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 23(6):569-575.
34. Chee KG, et al. (2007) The AKT inhibitor perifosine in biochemically recurrent prostate cancer: A phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer 5(7):433-437.
35. Yap TA, et al. (2011) First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29(35):4688-4695.
36. Zhang B, Kirov S, Snoddy J (2005) WebGestalt: An integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 33(web server issue): W741-748.
37. Liu Q, Turner KM, Alfred Yung WK, Chen K, Zhang W (2014) Role of AKT signaling in DNA repair and clinical response to cancer therapy. Neuro-oncol 16(10):1313-1323.
38. Shiloh Y, Ziv Y (2012) The ATM protein: The importance of being active. J Cell Biol 198(3):273-275.
39. Mirimanoff RO (2014) High-grade gliomas: Reality and hopes. Chin J Cancer 33(1):1-3.
40. Beroukhim R, et al. (2007) Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proc Natl Acad Sci USA 104(50): 20007-20012.
41. Smyth GK, Yang YH, Speed T (2003) Statistical issues in cDNA microarray data analysis. Methods Mol Biol 224:111-136.
42. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc, B 57(1):289-300.